[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534393":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":27,"locations":31,"responsibleParty":37,"collaborators":31,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":31,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":31,"enrollmentInfo":48,"targetDuration":31,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":31,"overallStatus":58,"whyStopped":31,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":31},{"fullName":5,"class":6},"Beijing 302 Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Combination of PTCy and ATG for GVHD prophylaxis","EXPERIMENTAL","ATG (anti-thymocyte globulin, rabbit; 5 mg\u002Fkg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg\u002Fkg, day -5; 2.5 mg\u002Fkg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg\u002Fkg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.",[13],"Drug: Cyclophosphamid",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Cyclophosphamid","ATG (anti-thymocyte globulin, rabbit; 5 mg\u002Fkg, day -5 to -2) was used in matched sibling donor-HSCT. ATG (1.5 mg\u002Fkg, day -5; 2.5 mg\u002Fkg, day -4; mathematical function was then exploited to determine the total targeted ATG dose on day -3 to -2 based on concentrations of active ATG on day -5 to -4) was used in both haploidentical donor-HSCT and mismatched unrelated donor-HSCT. Reduced-dose PTCy (two doses of 14.5 mg\u002Fkg Cy was given on days +3 and +4 post-HSCT) was used of GVHD prophylaxis.",[9],[21],"Anti-thymocyte globulin",[23],{"name":24,"affiliation":25,"role":26},"Xiaoning Gao, Doctor","Chinese PLA General Hospital","PRINCIPAL_INVESTIGATOR",[28,33],{"name":24,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","+86-010-66947169",null,"gaoxn@263.net",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},"Yuxin Wang, Doctor","15147159987","wyx15147159987@163.com",{"type":38,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100534393","phase-2-combination-of-atg-based-conditioning-regimen-and-ptcy-for-gvhd-prevention-in-allo-hsct-after-pd-1-blockade-100534393",false,"NCT06238245","Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade","A Prospective, Single-Arm Clinical Study of Anti-thymocyte Globulin-based Conditioning Regimen Combined With Post-Transplantation Cyclophosphamide for GVHD Prevention in Allogeneic HSCT After PD-1 Blockade","Inclusion Criteria:\n\n* (1) age ≥ 18 years old, regardless of gender;\n* (2) patients with hematological malignancies (including lymphoma, leukemia, myelodysplastic syndrome, etc.) who had received at least one course of PD-1 antibody treatment;\n* (3) patients with indications for allo-HSCT, available donors (including matched sibling donors, haploidentical donors and unrelated donors), and no contraindications for transplantation;\n* (4) patients suitable for conventional Bu\u002FFlu conditioning regimen;\n* (5) no serious heart, liver, kidney, lung and other important organ diseases;\n* (6) Eastern Cooperative Oncology Group (ECOG) performance status score 0-2;\n* (7) Hematopoietic stem cell transplantation comorbidity index (HCT-CI) score was 0-3;\n* (8) expected survival time of at least 12 weeks;\n* (9) women who are not pregnant or breastfeeding;\n* (10) voluntary participation in clinical research; They or their legal guardians were fully aware of the study and signed informed consent. Willing to follow and complete all trial procedures;\n\nExclusion Criteria:\n\n* (1) pregnant or lactating women;\n* (2) other serious conditions that may limit enrollment (e.g., advanced infection, etc.);\n* (3) unable to understand and follow the study protocol or sign the informed consent form.","ALL","18 Years",{"count":49,"type":50},22,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","The aim of this study is to evaluate the efficacy and safety of anti-thymocyte globulin combined with PTCy (post-HSCT cyclophosphamide, PTCy) in preventing graft-versus-host disease (GVHD) in allo-HSCT patients after anti-PD-1(anti-programmed cell death protein 1) antibody treatment. In this study, patients with hematological malignancies who needed to receive allo-HSCT after PD-1 antibody treatment were selected as the research subjects. Fludarabine and Busulfan was used as the conditioning regimen, and the dose of ATG (anti-thymocyte globulin, ATG) combined with PTCy was used as the GVHD prevention regimen. The aim of this study is to reduce the incidence of Regimen-Related Toxicity and GVHD without affecting engraftment and relapse, thereby reducing non-relapse mortality and further improving the survival of patients.",[56,57],"Graft-versus-host Disease","Hematological Malignancies","NOT_YET_RECRUITING","2024-02-19",{"date":61,"type":62},"2024-02-20","ACTUAL",{"date":64,"type":50},"2024-02-28",{"date":66,"type":50},"2026-06-30",{"name":5,"class":6}]